ReviewFrontiers in medical technology2026
China's regulatory regime for medical biotechnology: evolution, challenges, and future perspectives.
Review in Frontiers in medical technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modern medical biotechnology, while reshaping human healthcare and enhancing social welfare, may also pose biological risks. During the past 40 years, China has made considerable strides in becoming a global leader in biotechnology, necessitating a systematic review of the evolution, current state, and challenges of its regulatory framework. This paper traces the policy trajectory and institutional evolution of China's medical biotech regulation and conducts a policy evaluation within the historical context based on a comprehensive review of laws, regulations, and ministerial rules issued since the 1980s. The biorisk management system is divided into three components and China's policy evolving process into three stages. The analysis is focused on the driving forces of the regulatory policies, the shift of regulatory philosophy, the expansion of regulatory coverage, the current legal and organizational frameworks, and the challenges faced. We find that China's medical biotech regulatory policies have evolved over the past 40 years into a comprehensive regime, spanning the full cycle of research, application and export and covering the dual dimension of security and ethics. It is now supported by multi-tiered laws and regulations, and executed by specialized coordination mechanisms. However, the existing system still falls short in addressing the risks of technological convergence, clarifying the regulatory boundary, strengthening ethical constraints, and enhancing public engagement. Accordingly, we recommend that the agility, clarity, and inclusiveness of China's medical biotech governance should be further improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.